Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05046613
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
Sponsor: Pfizer
View on ClinicalTrials.gov
Summary
The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
Official title: A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)
Key Details
Gender
FEMALE
Age Range
0 Years - Any
Study Type
OBSERVATIONAL
Enrollment
780
Start Date
2021-09-23
Completion Date
2034-04-30
Last Updated
2026-01-22
Healthy Volunteers
No
Conditions
Interventions
OTHER
Rimegepant
75mg
OTHER
Not taking Rimegepant
No rimegepant
Locations (1)
Evidera, a PPD business unit
Wilmington, North Carolina, United States